{'fraction_non_alphanumeric': 0.025896414342629483, 'fraction_numerical': 0.0, 'mean_word_length': 5.209876543209877, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Osteoarthritis of the knee and hip. Part II: therapy with ibuprofen and a review of clinical trials

Objectives  We review the pharmacological properties and clinical evidence pertaining to the efficacy of ibuprofen as a first‐line treatment in hip and knee osteoarthritis (OA). In the context of our previous paper's exploration of the aetiology and pathogenesis of OA as a basis for pharmacotherapy, we discuss the pharmacokinetics (PK) and clinical pharmacodynamics (PD) of ibuprofen relevant to OA.